News & Events

Read about our latest product developments and partnerships, industry advances and events.

Accera, Inc. to Support the Alzheimer's Foundation of America's National Memory Screening Day through On-line Awareness Effort

August 11, 2009

Donations for Alzheimer's Care will be made for each Web site Visit

Broomfield, CO, August 11, 2009 – Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system diseases, announced today the launch of its "Lost & Found" campaign, an on-line initiative whereby each visit to www.lostandfoundcampaign.com prompts a $1 donation by Accera to support the Alzheimer's Foundation of America (AFA).

Every AD patient, caregiver or family who visits the "Lost & Found" Web site may participate in this fundraising campaign by simply selecting an icon that represents something they have lost or forgotten that day. Clicking on an icon will trigger a donation from Accera to AFA at no cost to the individual participants. All funds generated throughout this initiative will be donated to AFA on November 17, 2009, "National Memory Screening Day," to further AFA's efforts to support individuals with Alzheimer's disease and their families. The Web site also contains information on current treatment therapies and educational links for patients and caregivers.

National Memory Screening Day, an annual initiative sponsored by AFA, provides free, confidential memory screenings to individuals concerned about memory loss with the objective of early detection and intervention. Qualified healthcare professionals offer the face-to-face screenings at convenient locations in communities across the nation.

"We are pleased to be the recipients of Accera's 'Lost & Found' campaign as we work to raise awareness about National Memory Screening Day," said Eric J. Hall, AFA's president and chief executive officer. "With the incidence of Alzheimer's disease escalating, AFA is extremely appreciative of those who understand the vital need for support services and the difference they can make for individuals with dementia and their families."

Steve Orndorff, Ph.D., President and CEO of Accera, Inc., stated, "Our goal through this effort is to signal to patients and caregivers that there are many people and companies, like Accera, dedicated to combating this devastating disease." He continued, "With the downturn of the economy, we wanted to enable individuals to make a contribution towards this effort without having to donate their own income. Through our initiative we hope to improve the quality of life for patients and caregivers."

"Lost & Found" submissions will be accepted on-line through November 13, 2009.

About Axona™

Axona is a first-in-class medical food for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease. Dispensed by prescription, Axona targets the metabolic deficiencies and imbalances associated with Alzheimer's disease by providing an alternative energy source for brain cells. With simple administration and once-a-day convenience, Axona is complementary to current Alzheimer's disease therapies. For more information about Axona, please visit www.about-axona.com or ask your physician.

About the Alzheimer's Foundation of America (AFA)

The Alzheimer's Foundation of America (AFA) is a nonprofit organization based in New York City that focuses on providing optimal care to individuals with Alzheimer's disease and related illnesses, and their families, and unites more than 1,200 member organizations nationwide that provide hands-on programs and services to meet the educational, social, emotional and practical needs of those affected by the disease. AFA's services include a toll-free hot line with counseling by licensed social workers, a free caregiver magazine, professional training and its signature annual National Memory Screening Day. For information, call 866-AFA-8484 or visit www.alzfdn.org.

About Alzheimer's Disease

Alzheimer's disease, the most common form of dementia, is a progressive and fatal disease. In the United States, 5.2 million people are living with AD, and it has become the seventh leading cause of death. The disease attacks brain cells, resulting in loss of memory, executive function and language skills.

AD significantly impacts millions of family members and other caregivers – mentally, physically and financially. The National Family Caregiver Alliance estimates that approximately 80 percent of caregivers provide unpaid assistance seven days a week. With the lack of innovative new medications for AD, both patients and caregivers are seeking alternatives to improve quality of life.

BacktoTop